Floatz logo

Recombinant Vesicular Stomatitis Virus-Expressing Human Interferon Beta And Sodium-Iodide Symporter

Recurrent Angioimmunoblastic T-Cell Lymphoma

Mayo ClinicvaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Recurrent Angioimmunoblastic T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Romidepsin
The Lymphoma Academic Research Organisation
Phase 3BB
Pembrolizumab
AstraZeneca
Phase 2B
Nivolumab
Mayo Clinic
Phase 2B
Epirubicin
AstraZeneca
Phase 2B
Ruxolitinib
Mayo Clinic
Phase 1CC
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta
Mayo Clinic
Phase 1CC
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 1CC

Same molecule, other indications

Recombinant Vesicular Stomatitis Virus-Expressing Human Interferon Beta And Sodium-Iodide Symporter is also rated in:

Advanced Clear Cell Renal Cell CarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Stage III Renal Cell Cancer AJCC v8Dormant
CCC
Indicative ·
53 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →